Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans.
A dose of 1,000 mg probenecid was administered orally to 14 human volunteers in order to quantify the maximal rate of formation and excretion of probenecid acyl glucuronide in the urine. Probenecid showed dose-dependent pharmacokinetics. Plasma protein binding of probenecid was high, being somewhat higher in males (90.7 +/- 1.4%) than in females (87.9 +/- 1.4%; p = 0.0019). It was shown that probenecid is metabolized by cytochrome P-450 into at least two phase I metabolites. Each of the metabolites accounted for less than 12% of the dose administered; the main metabolite probenecid acyl glucuronide, representing 42.9 +/- 13.2% of the dose, was only present in urine and not in plasma. The renal excretion rate-time profile of probenecid acyl glucuronide showed a plateau value in the presence of an acidic urine pH. This plateau value was maintained for about 10 h at the dose of 1,000 mg. The height of the plateau value depended on the individual and varied between 250 and 800 micrograms/min (15-50 mg/h). It was inferred that probenecid acyl glucuronide is formed in the kidney during blood-to-lumen passage through the tubular cells. We conclude that the plateau value in the renal excretion rate of probenecid glucuronide reflects its Vmax of formation.
Vree
T B
TB
Department of Clinical Pharmacy, Academic Hospital Nijmegen Sint Radboud, The Netherlands.
Van Ewijk-Beneken Kolmer
E W
EW
Wuis
E W
EW
Hekster
Y A
YA
Broekman
M M
MM
D000284:Administration, Oral; D000328:Adult; D005260:Female; D005965:Glucuronates / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011339:Probenecid / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*; D012016:Reference Values; D012727:Sex Characteristics; D013997:Time Factors
D005965:Glucuronates; D011339:Probenecid